Product Description
EMB-01 is a novel bispecific antibody developed based on EpimAbÕs proprietary FIT-Ig¨ platform to simultaneously target EGFR and cMet on tumor cells. The resulting highly potent and durable anti-tumor effect in animal models encouraged EpimAb to rapidly advance EMB-01 to the clinic where it is currently being investigated in oncology indications. (Sourced from: https://www.epimab.com/en/news/11)
Mechanisms of Action: EGFR Inhibitor,C-Met Inhibitor
Novel Mechanism: No
Modality: Bispecific Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Shanghai EpimAb Biotherapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, United States
Active Clinical Trial Count: 3
Highest Development Phases
Phase 2: Carcinoid Tumor|Gastrointestinal Cancer|Non-Small-Cell Lung Cancer